Homocysteinemia as a risk factor of diabetic nephropathy in children and adolescents
https://doi.org/10.18705/1607-419X-2008-14-4-320-323
Abstract
This article summarizes data on homocysteinemia and its influence on vascular pathologic changes in patients with different diseases including diabetes type 1 and type 2. The role of homocystein as an independent risk factor for diabetic nephropathy in children and adolescents is discussed. The problem of homocysteinemia treatment is reviewed.
About the Author
Zh. V. Shutskaya
Municipal Diabetes Center for Children and Adolescents, municipal clinics № 44
Russian Federation
Russian Federation
References
1. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.
2.
3. Montalescot G, Ankri A, Chadefaux-Vekemans B.: Plasma homocysteine and the extent of atherosclerosis in patients with coronary arthery disease. Int J Cardiol 1997;60:295-300.
4.
5. Дедов И. И., Кураева Т. Л., Петеркова В. А. Сахарный диабет у детей и подростков. М: ГЭОТАР Медиа;2007;96-99.
6.
7. Дедов И. И., Шестакова М. В. Диабетическая нефропатия. М: Универсум Паблишинг; 2000:80-98.
8.
9. Finkelstein J. Methionine metabolism in mammals. J Nutr Biochem 1990;1:228-37.
10.
11. Костюченко Г.И., Баркаган З.С. Диагностика и методы коррекции гипергомоцистеинемии в кардиологической практике. Методические указания. 2003:20.
12.
13. Chang L, Xu J, Yu F, Zhao J, Tang X, Tang C. Taurine protected myocardial mitochondria injury induced by hyperhomocysteinemia in rats. Amino Acids 2004;27(1):37-48.
14.
15. Brattstrom L, Wilcken DEL, Ohrvik J, Brudin L: Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. Circulation 1998;98:2520-26.
16.
17. Blom H. Mutated 5,10-methylenetetrahydrofolate reductase and moderate hyperhomocysteinaemia. Eur J Pediatr 1998;57(2):131-34.
18.
19. Gudnason V, Stansbie D, Scott J, Bowron A, Nicaud V, Humphries S. C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentrations in different European populations (EARS group). Atherosclerosis 1998;136:347-54.
20.
21. Ali N. S, Powell J., Swaminathan R., Markus H.S. The relantionship between MTHFR genotype, serum homocysteine and folat levels. Biochem Sos Trans 1997;25:386.
22.
23. Fodinger M, Wagner OF, Horl WH, Sunder-Plassmann G. Recent insights into the molecular genetics of the homocysteine metabolism. Kidney Int 2001;59(78):238-42.
24.
25. Refsum H, Smith AD. Homocysteine, B vitamins and cardiovascular disease. N Engl J Med 2006;355:207.
26.
27. Bazzano LA, Reynolds K, Holder KN, et al. Effect of folic acid supplementation on risk of cardiovascular diseases: A meta-analysis of randomized controlled trials. JAMA 2006;296:2720-26.
28.
29. McCully КS. Homocysteine, folate, vitamin B6 and cardiovascular disease. JAMA 1998;279(5):392-93.
30.
31. Perna AF, Ingrosso D, Castaldo P et al. Homocysteine and transmethylations in uremia. Kidney Int 2001;59(78):230-33.
32.
33. Blundell G, Jones BG, Rose FA, Tudball N. Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis 1996;122:163-72.
34.
35. Bonaa KH, Njolstad I, Ueland PM. NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354(15):1578-88.
36.
37. Arruda V, von Zuben P, Chiaparini L The mutation Ala-Val in methylenetetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Tromb Haemost 1997;77:818-21.
38.
39. Kazemi M, Eshraghian K, Omrani G Homocysteine level and coronary artery disease. Angiology 2006;57(1):9-14.
40.
41. Boushey C, Beresford S, Omenn G, Motulsky A A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274(13):1049-1057.
42.
43. Stangl V, Baumann G, Stangl К. Coronary atherogenic risk factors in women. Eur Heart J 2002;23(22):1738-52.
44.
45. Buccianti G, Raselli S, Baragetti I et al. 5-methyltetrahydrofolate restores endothelial function in uraemic patients on convective haemodialysis. Nephrol Dial Transplant 2002;17(5):857-64.
46.
47. Bollander-Gonnaile C. Focus on homocysteine and the vitamin ivolved in its metabolism. Springer Verlag France 2002:217.
48.
49. Neugebauer S., Baba T., Watanabe T. Defective homocysteine metabolism as a risk factor for diabetic retinopathy. Lancet 1997;34:473-74.
50.
51. Neugebauer S, Baba T, Watanabe T. Methylenetetrahydrofolate reductase gene polymorfism as a risk factor for diabetic nephropathy in NIDDM patients. Lancet 1998;352:452.
52.
53. Kark J, Selhub J, Bostom A, Adler B, Rosenberg I. Plasma homocysteine and all-cause mortality in diabetes.Lancet 253:1936-37.
54.
55. Jacobs R.L., House J.D., Brosnan M.E., Brosnen J.T.: Effects of streptozotocin-induced diabetes and insulin treatment on homocystein metabolism in the rat. Diabetes 1998;47:1967-70.
56.
57. Schwartz E, Shcherbak N, Shutskaya Zh, Sheidina A, Larionova V Methylentetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in IDDM patients. Moleс gen and metabol 1999;68:375-78.
58.
59. Шуцкая Ж. В., Башнина Е. Б., Савенкова Н. Д. Распространенность диабетической нефропатии у больных с аллельными вариантами C667T полиморфизма гена МТГФР по результатам 7-летнего катамнеза. Нефрология 2008;12(1):36-39.
60.
61. Matteucci E., Rossi L., Marini S. Blood levels of total homocysteine in patients with type 1 diabetes (with no complications, diabetic nephropathy and/or retinopathy) and in their non-diabetic relatives. Nutr Metab Cardiovasc Dis 2002;12(4):184-89.
62.
63. Потемкин В. В., Кубатиев А. А., Абрамова Е. А., Томилова Е. Н., Гудукина Г. Н. Роль гомоцистеина в патогенезе сосудистых осложнений при сахарном диабете 2-го типа. Проблемы эндокринологии. 2007;53(3):10-13.
Review
For citations:
Shutskaya Zh.V. Homocysteinemia as a risk factor of diabetic nephropathy in children and adolescents. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2008;14(4):320-323. (In Russ.) https://doi.org/10.18705/1607-419X-2008-14-4-320-323
Views:
777
Email this article 